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Increased	incidence	of	oncological	diseases	has	led	
to	the	search	of	the	new	efficient	therapies	for	malignant	
neoplasia.	One	of	the	advanced	methodologies	of	the	
tumor	therapy	is	development	of	such	approaches	that	
involve	not	only	a	direct	cytotoxic	effect	on	the	tumor	
cells,	but	also	consider	activation	of	 the	endogenous	
antitumor	mechanisms	[1].	One	of	 the	most	efficient	
applications	was	 the	use	of	 the	so-called	biological	
response	modifiers	 (BRMs),	such	as	 the	culture	Co-
rinebacterium parvum,	anti-tuberculosis	vaccine	BCG	
[2],	as	well	as	the	biologically	аctive	compounds	mainly	
of	the	polysaccharidic	nature	derived	from	bacteria	and	
fungi,	such	as	prodigiosan,	mannan,	glucan,	muramyldi-
peptide,	etc	[3].	In	the	last	decade,	much	attention	has	
been	given	to	the	investigation	of	the	antitumor	activity	
of	the	natural	non-specific	immunomodulators	—	fun-
gal	(1→3)-β-D-glucans	[4–7].	Glucans	are	structurally	
distinct	polysaccharides	consisting	of	D-glucose	units	
linked	by	(1→3)-β	and	(1→6)-β	glycosidic	linkages.	Many	
experimental	data	corroborate	 the	ability	of	 (1→3)-β-
D-glucans	 to	non-specifically	stimulate	cellular	and	
humoral	components	of	the	immune	system	[8].	One	of	
the	(1→3,1→6)-β-D-glucans,	lentinan,	isolated	from	the	
oriental	edible	mushroom	shiitake	or	Lentinus edodes,	
was	admitted	in	Japan	for	application	in	clinical	antitumor	
therapy	[9–11].	Another	fungal	glucan,	(1→3,1→6)-β-D-
glucan	isolated	from	the	cell	wall	of	baker’s	yeast	Sac-
charomyces cerevisiae	has	attracted	attention	of	many	
researchers	due	to	its	ability	to	enhance	the	functional	
status	of	macrophages	and	neutrophils	 [12],	modify	
immunosuppression	[13],	increase	resistance	to	infec-
tions	by	Gram-negative	bacteria	[14],	as	well	as	exert	
antitumor	activity	 [15,	16].	Since	(1→3)-β-D-glucans	
consist	solely	of	glucose,	they	are	not	toxic	to	animals	
and	humans,	however	insolubility	in	water	hinders	their	
application	 in	animal	models	and	humans.	 In	order	to	
circumvent	this	obstacle,	we	have	synthesized	several	
water-soluble	derivatives	of	yeast	β-D-glucan	including	
carboxymethylated	and	sulfoethylated	ones	[17,	18].	In	a	
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Aim: One of the advanced methodologies of the tumor therapy is the application of the so-called biological response modifiers used for 
activation of the endogenous antitumor mechanisms and combined with classical cytotoxic agents. The aim of this work was the inves-
tigation of the effect of sulfoethylated (1→3)-β-D-glucan (SEG) in the treatment of experimental murine leukoses in combination with 
cyclophosphamide (CPA) and its ability to modulate the activity of lysosomal enzymes in tumor tissues. Materials and Methods: The solid 
forms of inoculated murine leukoses P388 and L1210/1 were transplantated to male DBA/2 mice. The therapy was performed by treating 
animals with CPA (Biokhimik, Saransk, Russia) alone or in combination with SEG (Institute of Chemistry, Slovak Academy of Sciences, 
Slovakia). CPA was administered in saline as a single intraperitoneal (ip) injection on the 10th day after tumor transplantation; SEG was 
administered to mice ip 3 days after tumor transplantation with the intervals in 3 days. The therapy effect was estimated by measuring of 
solid tumor volume. Activity of the cysteine proteases — cathepsins B and L — was measured fluorometrically using fluorescent substrates 
Z-Arg-Arg-MCA and Z-Phe-Arg-MCA (Sigma, USA), respectively. The apoptosis was estimated evaluating the number of cells with 
fragmented nuclei using optical microscope. Results: It has been demonstrated that application SEG leads to inhibition of tumor growth 
and potentiates therapeutic action of CPA, especially at repeated administrations during the whole treatment/observation At addition of 
SEG, therapeutic effect of a one-half reduced dose of CPA is equal or higher than that of the full dose. Therapeutic action of CPA and SEG 
on the studied tumors is realized predominantly through induction of apoptosis and is accompanied by a substantial increase of the activity 
of cysteine proteases cathepsins B and L in tumor tissues. The highest cathepsin B and cathepsin L activity in tumor tissue accompanied 
with the strongest inhibition of tumor growth. It is suggested that this phenomenon is due to the infiltration of the macrophages rich in the 
named enzymes into the tumor, where they phagocytize the apoptotic cells and tissue debris. Conclusion: Utilization of this polysaccharide 
BRM, sulfoethylated (1→3)-β-D-glucan, might potentially enhance efficiency of antitumor therapy with standard cytostatics without a 
need of substantial increase of their dosage and hence avoiding their toxic side-effects.
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previous	paper,	we	have	demonstrated	the	possibility	of	
enhancement	of	antitumor	activity	of	cyclophosphamide	
by	means	of	addition	of	the	carboxymethylated	(1→3)-β-
D-glucan	in	the	Lewis	lung	carcinoma	model	[1].	In	this	
work,	we	have	investigated	the	effect	of	another	soluble	
(1→3)-β-D-glucan	derivative,	sulfoethylated	(1→3)-β-D-
glucan	(SEG),	in	the	treatment	of	experimental	murine	
leukoses,	its	synergistic	action	with	cyclophosphamide,	
as	well	as	its	ability	to	modulate	the	activity	of	lysosomal	
enzymes	in	tumor	tissues	in	the	process	of	therapy	of	
leukoses.
matErials and mEthods
Preparation of SEG. The	water-insoluble	(1→3)-
β-D-glucan	was	isolated	from	the	commercial	baker’s	
yeast	 biomass	 purchased	 from	Slovlik	 (Trenčín,	
Slovakia).	Yeast	cells	were	treated	with	6%	NaOH	at	
60	 °C	 followed	by	4%	phosphoric	acid	extraction	at	
room	temperature	as	previously	described	[19].	After	
the	 removal	of	all	 soluble	material,	β-D-glucan	was	
left	as	 the	 insoluble	 residue.	Sulfoethylation	of	 the	
insoluble	β-D-glucan	was	performed	according	 to	
Chorvatovičová	et	al.	[20].
Animals and tumors. Male	DBA/2	mice,	3–4	months	
of	age	used	 in	 the	experiments	were	obtained	 from	
Research	Institute	of	Pharmacology	Siberian	Branch	of	
RAMS	(Tomsk,	Russia).	The	animals	were	kept	in	plastic	
cages	in	groups	of	8–10	at	natural	illumination	and	had	free	
access	to	a	standard	pellet	diet	(Laboratorsnab,	Moscow,	
Russia)	and	water.	Two	experimental	tumor	models	were	
used:	transplantable	murine	leukoses	P-388	and	L1210/1.	
The	tumors	were	received	from	the	experimental	animal	
laboratory	of	the	Institute	of	Cytology	and	Genetics	Si-
berian	Branch	of	RAS	(Novosibirsk,	Russia).	Leukosis	
L1210/1	is	a	version	of	the	leukosis	L1210	obtained	after	
a	series	of	in vitro	passages	of	initial	tumor	and	charac-
terized	by	rather	benign	behavior	and	absence	of	visible	
macroscopic	signs	of	generalization	[21].	The	work	with	
animals	was	approved	by	Ethic	committee.
 Tumor transplantation and animal treatment. 
The	cryoconserved	suspensions	of	tumor	cells	were	
thawed	and	implanted	into	abdominal	cavity	of	DBA/2	
mice	and	the	developed	ascites	were	used	for	trans-
plantation	 to	 the	experimental	animals.	The	ascites	
were	diluted	with	20	volumes	of	physiological	saline	
and	1	ml	of	a	suspension	(1.5–1.7	×	106	tumor	cells)	
was	inoculated	intramuscularly	(im)	into	animal’s	right	
thigh.	In	each	experiment,	shortly	after	tumor	trans-
plantation	the	animals	were	divided	into	four	groups,	
one	of	which	(group	1)	was	a	control	group	and	three	
other	groups	(2	to	4)	were	subjected	to	therapy.	The	
therapy	was	performed	by	treating	animals	with	cyc-
lophosphamide	 (CPA,	Biokhimik,	Saransk,	Russia)	
alone	 (groups	2	and	3)	or	 in	combination	with	SEG	
(group	4).	CPA	was	administered	in	saline	as	a	single	
intraperitoneal	(ip)	injection	on	the	10th	day	after	tumor	
transplantation	at	the	doses	of	20	and	40	mg/kg	in	one	
experiment	and	25	and	50	mg/kg	in	other	experiments.	
SEG	was	dissolved	in	saline	and	administered	to	mice	
ip	3	days	after	tumor	transplantation	three	times	in	one	
experiment	and	5–7	times	in	other	experiments.	Each	
single	dose	of	SEG	was	25	mg/kg	and	the	 intervals	
between	the	individual	injections	were	3	days.	
Estimation of tumor growth. Three	perpendicular	
diameters	of	the	tumor	were	measured	with	a	caliper	
and	 tumor	volume	was	calculated	by	multiplication	
of	 their	 values.	When	 the	mice	were	sacrificed,	 the	
excised	tumor	nodules	were	homogenized	in	buffered	
0.1%	Triton	X-100	solution	for	subsequent	determina-
tion	of	proteases	activity.
Cysteine protease assay. Activity	of	the	cysteine	
proteases	—	cathepsins	B	and	L	—	was	measured	
fluorometrically	as	previously	described	by	Svechnikova	
et	al.	[22].	Shortly	activityofcathepsinsBandLwereas-	 	 	 	 	 	 	
sessed	in	the	tumor	tissue	using	fluorescent	substrates	
Z-Arg-Arg-MCA	and	Z-Phe-Arg-MCA	(Sigma,	USA),	
respectively.	At	assay	of	cathepsin	L	a	selective	inhibitor	
of	cathepsin	B	—	CA-074	(kind	gift	of	Prof.	N.	Katunuma,	
Japan)	was	added	 into	 incubation	mixture.	Fluores-
cence	was	measured	at	355	nm	(excitation)	and	460	nm	
(emission)	using	a	fluorescent	spectrophotometer	Per-
kin-Elmer	650–10S	(Japan).	The	results	were	expressed	
as	nmol	of	methylcoumarylamide	(MCA)/	min	per	mg	
protein.	The measurements were carried out in the	 	 	 	 	 	 	
treated	animals	on	the	3rd	day	after	CPA	administration,	
i.	e.	13	days	after	tumor	implantation.
Apoptosis assay. In	order	to	evaluate	apoptosis,	
mice	were	euthanized	3	days	after	administration	of	
CPA,	tumors	were	extracted	and	minced	with	scissors	
in	physiological	solution.	The	resulting	suspension	was	
filtered	through	nylon	sieve.	Upon	3	min	centrifuga-
tion,	sedimented	cells	were	fixed	in	Carnois	fluid,	dyed	
with	acetocarmine	in	40%	acetic	acid	and	the	number	
(percentage)	of	cells	with	fragmented	nuclei	(cells	in	
the	preterminal	apoptosis	phase)	was	evaluated	using	
optical	microscope.	It	should	be	however	pointed	out	
that	this	method	yields	underestimated	data	since	it	
does	not	take	into	account	cells	totally	disintegrated	
to	apoptotic	corpuscles	[23].
Statistical analysis. Statistical	 analysis	was	
performed	using	Wilcoxon	—	Mann	—	Whitney	non-
parametrical	criteria.
rEsults
Fig.	1	illustrates	the	results	of	the	first	experiment	
with	leukosis	Р-388.	As	can	be	seen,	on	the	10th	day	
after	tumor	transplantation	its	size	was	smaller	in	mice	
treated	with	SEG	 in	comparison	with	 those,	which	
did	not	receive	the	polysaccharide.	During	3–4	days	
upon	administration	of	CPA	at	all	modes	of	treatment	
applied,	 the	 tumor	size	has	decreased,	however	 it	
started	to	grow	again,	and	this	growth	was	especially	
pronounced	in	mice	of	the	second	group,	which	were	
administered	CPA	alone	in	a	low	dose	(25	mg/kg).	Mice	
from	the	fourth	group,	which	received	the	same	dose	
of	CPA	in	combination	with	SEG	revealed	smaller	size	
of	tumor	up	to	the	14th	day	of	the	experiment	than	the	
mice	from	the	third	group	treated	with	higher	dose	of	
CPA	alone	(50	mg/kg),	while	on	the	14th	day	the	size	of	
tumor	was	similar	in	mice	of	these	two	groups.	How-
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ever,	afterwards	 tumors	 in	mice	of	 the	 fourth	group	
grew	faster	than	in	the	animals	of	group	3	(see	Fig.	1).	
Thus,	application	of	low	dose	of	CPA	after	three	admin-
istrations	of	SEG	exerted	better	effect	than	higher	dose	
of	CPA	only	during	the	early	phase	of	the	experiment,	
while	later	this	advantage	disappeared.	
fig. 1. Effect	of	cyclophosphamide	and	sulfoethylated	(1→3)-β-
D	glucan	on	tumor	volume	in	mice	with	leukosis	P-388
*P < 0.05 compared	to	the	untreated	mice.	#	P	<	0,05	compared	
to	the	mice	treated	with	CPA	50	mg/kg.	$	P	<	0.05	compared	to	
the	mice	treated	with	CPA	25	mg/kg	+	SEG.	7–10	mice	in	each	
group.	CPA	was	administered	to	mice	on	the	10th	day	after	tumor	
transplantation.	SEG	was	administered	to	mice	on	the	3rd,	6th,	and	
9th	days	after	tumor	transplantation	(25	mg/kg).	Tumor	volume	
was	calculated	as	the	product	of	multiplication	of	3	perpendicular	
diameters	of	tumor	node	in	murine	thigh.
Taking	 this	 into	account,	 in	 the	 following	experi-
ment	SEG	was	applied	both	before	(on	the	3rd,	6th,	and	
9th	days),	as	well	as	after	(on	the	12th	and	15th	days)	
administration	of	CPA,	which	was	similarly	to	the	first	
experiment	injected	in	a	dose	of	25	mg/kg	on	the	10th	
day	after	 transplantation	of	 leukosis	Р-388.	At	 this	
scheme	of	treatment,	therapeutic	effect	of	the	com-
bined	application	of	low	dose	CPA	and	SEG	was	simi-
lar	to	that	of	the	treatment	using	higher	dose	of	CPA	
throughout	whole	duration	of	the	experiment.	Tumor	
volume	at	the	end	of	the	monitoring	(on	the	17th	day)	
was	0.42	±	0.125	cm3	(combined	CPA	and	SEG	appli-
cation)	and	0.48	±	0.090	cm3	(application	of	50	mg/kg	
CPA	alone),	while	in	mice	that	received	25	mg/kg	CPA	
alone	tumor	volume	reached	1.61	±	0.223	cm3	at	the	
end	of	the	experiment	and	all	control	(untreated)	ani-
mals	did	not	survive	till	the	17th	day.
Similar	results	have	been	obtained	in	the	experi-
ments	 involving	 leukosis	L1210/1.	Using	 this	 tumor	
model,	CPA	 in	 doses	of	 20	mg/kg	and	40	mg/kg	
was	administered	once	on	 the	10th	day	after	 tumor	
transplantation,	while	 taking	 into	account	 results	of	
the	preceding	experiments,	SEG	was	applied	to	the	
animals,	which	received	40	mg/kg	CPA,	seven	times	
during	the	whole	monitoring	—	on	the	3rd,	6th,	9th,	12th,	
15th,	18th,	and	21st	days	after	tumor	implantation.
As	can	be	seen	in	Fig.	2,	implants	of	L1210/1	tumor	
continued	 to	grow	during	 the	 first	 three	days	after	
injection	of	CPA,	while	within	the	following	three	days	
tumor	size	decreased	to	one	half	(at	20	mg/kg	dose)	
or	to	one	fourth	of	the	initial	size	(at	40	mg/kg)	and	the	
tumor	began	to	grow	again	after	4	or	7	days,	respec-
tively,	with	practically	similar	 rate	as	can	be	 judged	
upon	 the	slope	of	 the	curves.	 In	contrast	 to	 that,	 in	
mice,	which	were	administered	CPA	and	SEG	together,	
tumors	started	to	diminish	immediately	upon	applica-
tion	of	CPA	and	at	the	end	of	the	experiment,	when	in	
the	group	of	mice	treated	with	CPA	alone	tumor	size	
doubled	in	two	days,	at	a	combined	administration	of	
CPA	and	SEG	tumor	grew	only	gradually	and	the	size	
increase	was	insignificant	(see	Fig.	2).	
fig. 2. Effect	of	CPA	and	SEG	on	 tumor	volume	 in	mice	with	
leukosis	L1210/1
*P < 0,05	compared	with	the	untreated	mice.#P	<	0,05	compared	
with	the	mice	treated	with	CPA	40	mg/kg	+	SEG.	7–10	mice	in	each	
group.	CPA	was	administered	to	mice	on	the	10th	day	after	tumor	
transplantation.	SEG	was	administered	to	mice	on	the	3rd,	6th,	9th,	
12th,	15th,	18th,	and	21rd	days	after	tumor	transplantation	(25	mg/kg).	
Tumor	volume	was	calculated	as	the	product	of	multiplication	of	
3	perpendicular	diameters	of	tumor	node	in	murine	thigh.
The	 results	of	 the	 investigation	of	 the	activity	of	
the	cysteine	proteases	—	cathepsins	B	and	L	—	in	the	
tumor	tissue	of	mice	with	implanted	leukoses	Р-388	
and	L1210/1	on	the	3rd	day	after	CPA	injection	are	pre-
sented	in	the	Table.	As	can	be	seen,	untreated	animals	
with	either	of	 the	 tumors	 revealed	practically	equal	
activities	of	the	individual	cathepsins	and	after	the	on-
set	of	treatment	activity	of	cathepsins	increased	in	all	
experimental	groups,	while	the	observed	increase	was	
more	pronounced	with	Р-388	tumor	in	comparison	with	
the	L1210/1.	The	highest	cathepsin	B	and	cathepsin	L	
activity	in	tumor	tissue	accompanied	with	the	strongest	
inhibition	of	tumor	growth	was	detected	in	the	animals	
treated	with	CPA	and	SEG	(Table).	
Table. ��mor weig�t and cysteine proteases activity in t�mor transp�ants 
of �e��osis P388 and L1210/1 (M ± S.D.)
Gro�p of anima�s ��mor weig�t (g)
Cat�epsin B 
(nmo� MC�/min 
per mg of protein)
Cat�epsin L (nmo� 
MC�/min per mg 
of protein)
Le��osis P388
1. Untreated anima�s 1.6 ± 0.11 
(100%)
0.16 ± 0.040 
(100%)
0.04 ± 0.004 
(100%)
2. CP�, 50 mg/�g × 1 1.0 ± 0.13*** 
(62.5%)
0.51 ± 0.159 
(319%)
0.11 ± 0.025* 
(275%)
3. CP�, 25 mg/�g × 
1 + S�G, 25 mg/�g × 4
0.6 ± 0.14*** 
(37.5 %)
0.74 ± 0.060*** 
(463%)
0.13 ± 0.009*** 
(325%)
Le��osis 1210/1
1. Untreated anima�s 4.7 ± 0.31 
(100%)
0.18 ± 0.017 
(100%)
0.04 ± 0.004 
(100%)
2. CP�, 40 mg/�g × 1 3.1 ± 0.25** 
(66.0%)
0.35 ± 0.041** 
(194%)
0.06 ± 0.004*** 
(150%)
3. CP�, 40 mg/�g × 
1 + S�G, 25 mg/�g × 4
1.8 ± 0.19***## 
(38.3%)
0.46 ± 0.022***# 
(256%)
0.07 ± 0.002***# 
(175%)
Notes: CP was administered to mice on t�e 10t� day after t�mor trans�
p�antation; S�G was administered on t�e 3rd, 6t�, 9t�, and 12t� days after 
t�mor transp�antation. In parent�eses: percentage re�ative�y to t�e �n�
treated gro�p. ��e n�mber of anima�s in eac� gro�p was 7–10. *P < 0.05, 
**P < 0.01, ***P < 0.001 compared to t�e �ntreated gro�p, #P < 0.05, 
##P < 0.01 compared to t�e CP��treated gro�p.
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Shape	of	 the	curves	 in	Fig.	2	 (increase	of	 tumor	
volume	in	the	first	2–3	days	after	CPA	injection	and	the	
subsequent	regression)	may	suggest	that	the	therapeutic	
effect	in	the	used	model	is	to	a	significant	extent	medi-
ated	through	induction	of	apoptosis	of	the	tumor	cells	
[23].	Upon	performing	the	analysis	of	cell	suspensions	
obtained	from	the	implanted	L1210/1	tumor	on	the	3rd	day	
after	beginning	of	the	treatment,	it	has	been	found	that	
indeed	the	predominant	portion	of	 the	cells	contains	
picnotic	and	fragmented	nuclei,	i.e.	are	in	apoptotic	state.	
Number	of	such	cells	in	the	tumors	of	the	treated	mice	
was	3–4	times	higher	than	in	the	control	animals,	and	in	
mice	treated	with	CPA	after	three	SEG	administrations	
this	number	was	significantly	higher	than	in	those	that	
received	CPA	alone	(Fig.	3,	а).	As	can	be	seen	in	Fig.	3,	b,	
leukosis	P388	is	also	susceptible	to	CPA-induced	apop-
tosis	(effect	of	a	combined	administration	of	CPA	and	
SEG	was	not	studied	in	this	case).
fig. 3. Apoptosis	of	the	tumor	cells	in mice	with	L1210/1	and	
Р-388	 leukoses	3	days	after	CPA	administration:	a)	 L1210/1	
leukosis,	CPA	40	mg/kg;	b)	Р-388	leukosis,	CPA	50	mg/kg
discussion
The	results	presented	in	the	study	indicate	that	the	
prepared	sulfoethylated	derivative	of	yeast	cell	wall	
(1→3)-β-D-glucan	possesses	an	ability	to	significantly	
augment	the	therapeutic	action	of	CPA	in	the	murine	
lymphoid	tumors.	Multiple	applications	of	SEG	revealed	
enhanced	effect	 in	comparison	 to	 its	single	admin-
istration	simultaneously	with	CPA	 (data	not	shown)	
or	its	three-time	application	prior	to	injection	of	CPA. 
Since	protective	activity	of	the	glucans	is	known	to	be	
mediated	via	the	stimulation	of	the	immune	system	of	
the	host	 rather	 than	 through	direct	 interaction	of	 the	
polysaccharide	with	the	infective	agent	[4,	5,	8]	it	was	
not	anticipated	 that	application	of	SEG	alone	could	
affect	 tumor	growth	and	 therefore	 there	was	no	ex-
perimental	group	of	animals	that	received	SEG	alone.	
Nevertheless,	it	was	observed	that	besides	potentiating	
the	therapeutic	action	of	CPA,	SEG	itself	was	capable	
of	exerting	inhibitory	effect	on	tumor	growth:	upon	its	
three-time	administration	a	certain	retardation	of	 the	
implanted	tumor	growth	was	observed	already	prior	to	
the	onset	of	cytostatics	treatment	(Fig.	1	and	2).	The	
biological	effects	of	 (1→3)-β-D-glucans	are	 initiated	
through	 their	 recognition	and	binding	 to	 the	specific	
cell	surface	receptors:	CR3	[24]	lactosylceramide	[25]	
scavenger	receptors	[26]	and	dectin-1	[27].	Besides	
monocytes	and	macrophages,	presence	of	β-D-glucan	
receptors	has	been	established	also	on	the	neutrophiles	
[25,	28],	NK-cells	[29–31],	fibroblasts	[32]	and	some	
tumor	cells	[33].	Previously	we	demonstrated	that	SEG	
alone	suppressed	growth	of	susceptible	to	CPA	murine	
lymphosarcoma	[18].
What	mechanism	could	be	involved	in	its	inhibitory	
activity	on	tumor	growth?	The	antitumor	action	of	SEG	
could	be	ascribed	to	the	ability	of	yeast	β-D-glucan	
to	stimulate	release	of	 tumor	necrosis	 factor	TNF-α	
from	monocytes/macrophages,	as	we	have	previously	
demonstrated	[34].	Some	indications	of	the	additional	
mechanism	are	provided	by	the	results	of	the	current	
investigation	of	the	mechanism	of	death	of	the	tumor	
cells	and	of	the	activities	of	cathepsins	B	and	L	in	tumor	
tissues	of	the	treated	animals.	 Increased	content	of	
apoptotic	cells	in	the	tumors	subjected	to	the	treatment	
by	a	combination	of	CPA	and	SEG	in	comparison	with	
those	treated	with	CPA	alone	implies	that	SEG	is	able	
to	induce	apoptosis	in	susceptible	cells.	Augmented	
activity	of	the	lysosomal	proteases	in	tumor	tissues	is	
justified	if	these	enzymes	take	part	in	the	induction	or	
realization	of	apoptosis.	However	as	a	more	reason-
able	explanation	appears	to	be	a	suggestion	that	the	
observed	post-treatment	enhancement	of	activity	of	
cathepsins	B	and	L	in	tumor	tissues	results	not	from	
their	activation	in	tumor	cells,	but	rather	is	due	to	the	
increased	number	of	macrophages	 infiltrating	 the	
tumor	cells	to	resorb	dying	apoptotic	tumor	cells.	We	
are	currently	attempting	to	verify	this	hypothesis.	
In	conclusion,	combined	application	of	CPA	and	
SEG	resulted	 in	 the	enhanced	apoptosis	of	 the	 leu-
kemic	cells	and	was	accompanied	by	a	substantial	
increase	of	the	activity	of	cysteine	proteases	cathep-
sins	B	and	L	in	tumor	tissues.The	results	obtained	in	
the	present	work	demonstrate	that	at	addition	of	SEG,	
therapeutic	effect	of	a	one-half	reduced	dose	of	CPA	is	
equal	or	higher	than	that	of	the	full	dose	(Fig.	1	and	2).	
Thus,	utilization	of	 this	polysaccharide	BRM	might	
potentially	enhance	efficiency	of	antitumor	 therapy	
with	standard	cytostatics	without	a	need	of	substan-
tial	increase	of	their	dosage	and	hence	avoiding	their	
toxic	 side-effects.	These	 results	 together	with	 the	
previously	published	data	on	the	beneficial	effect	of	
administration	of	the	derivatives	of	yeast	β-D-glucan	
in	 the	antitumor	 therapy	of	 various	 types	of	cancer	
indicate	possible	 utilization	of	 these	preparations	
especially	at	a	combined	application	with	classical	
anticancer	agents.
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ПОТЕНЦИРУЮЩИЙ ЭФФЕКТ СУЛЬФОЭТИЛИРОВАННОГО 
(1→3)-β-d-ГЛИКАНА НА ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ 
ЦИКЛОФОСФАНА ПРИ ЭКСПЕРИМЕНТАЛЬНЫХ ЛЕЙКОЗАХ 
МЫШЕЙ
Цель: одним из перспективных методов противоопухолевой терапии является использование так называемых модификаторов 
биологического ответа, применяемых для активации эндогенных противоопухолевых механизмов и комбинируемых с 
классическими цитотоксическими препаратами. Цель данной работы — исследование эффекта сульфоэтилированного (1→
3)-β-D-гликана (SEG) при лечении экспериментальных лейкозов мышей в комбинации с циклофосфаном (СРА) и его способность 
модулировать активность лизосомных ферментов в опухолевой ткани. Материалы и методы: солидные формы перевиваемых 
лейкозов мышей Р388 и L1210/1 трансплантировали мышам-самцам DBA/2. Для лечения использовали СРА (Биохимик, 
Саранск, Россия) и его комбинацию с SEG (Институт химии Словацкой Академии Наук, Братислава, Словакия). СРА вводили 
внутрибрюшинно на 10 сут после перевивки опухолей; SEG вводили внутрибрюшинно начиная с 3 сут после трансплантации 
лейкозов с интервалом в 3 дня. Терапевтический эффект оценивали путем измерения объема солидной опухоли. Активность 
цистеиновых протеаз — катепсинов В и L — определяли флюориметрическим методом, используя флюоресцентные субстраты 
Z-Arg-Arg-MCA и Z-Phe-Arg-MCA (Sigma, США). Апоптоз оценивали по результатам подсчета клеток с фрагментированными 
ядрами в световом микроскопе. Результаты: в работе показано, что использование SEG приводит к торможению опухолевого 
роста и потенцирует терапевтический эффект СРА, особенно при повторном введении в течение всего лечения. В сочетании с SEG 
терапевтический эффект половинной дозы СРА равнозначен или превышает действие полной дозы цитостатика. Воздействие 
СРА и SEG на использованные в исследовании опухоли реализуется в основном через индукцию апоптоза и сопровождается 
существенным повышением активности цистеиновых протеаз катепсинов В и L в опухолевой ткани. Наиболее высокая 
активность катепсинов В и L сопровождается максимальным подавлением опухолевого роста. Предположительно это обусловлено 
инфильтрацией опухолевой ткани макрофагами с высоким содержанием вышеназванных ферментов, где они фагоцитируют 
клетки в апоптозе. Выводы: использование сульфоэтилированного (1→3)-β-D-гликана, нового модификатора биологического 
ответа дает возможность существенно повысить эффективность противоопухолевой терапии стандартными цитостатиками без 
повышения их дозы, что позволяет избежать побочных эффектов данных препаратов. 
Ключевые слова: лейкозы мышей, катепсины, дрожжевые гликаны, циклофосфан.
Copyrig�t © �xperimenta� Onco�ogy, 2006
